News Release:EPS Corporation(4282 TSE 1st section)
November 21, 2013

Notices for Business Policy Initiatives for Current Fiscal Term (24th Term)and Future Outlook

The announcement for business policy initiatives for the current fiscal term and future outlook for EPS Groupis as follows.

1. Business Policy Initiatives for Current Fiscal Term
In response to rapid changes in business environment related to the pharmaceutical and medical device
industries in recent years, as well as to ensure sustained growth for the company after 20 years in business, wehave reviewed our management structure and established a new foundation for future developments.

Amongthem, we have decided to restructure our businesses and strengthen the management structure of individualbusinesses.
Recognizing that this will be a tipping point in our management operations, we have especially positioned thisfiscal term as our “new year start”, by clarifying the responsibilities and authorities of each business segments
to promote self-management and achieving clarifications and executions of different functions across theGroup.
In addition, based on the experiences and lessons of the previous fiscal term, our priority for this fiscal term isto achieve the planned target figures steadily, while also giving sufficient consideration with regard to ourmedium-term management plan.

2. Clarification of Business Segments
Business segments have been clarified, as follows:Business Segment

Company NameEPS Corporation

Domestic CRO BusinessBusiness Outline
Holding Company Functions
CRO General Operation

EPMate Co., Ltd.

CRO Dispatch-type Operation

e-Trial Co., Ltd.

IT-based CRO Operation (EDC,etc)

Domestic SMO Business

EP-Mint Co., Ltd.

SMO Overall Operations

Domestic CSO Business

EP-PharmaLine Co., Ltd.
EPS International HoldingsCo., Ltd.

GR (Global Research) Business

MR Contract Operation
Drug-related Call Center Operations
GR Operation Management

EPS International Co., Ltd.

CRO General Operation (China)

EPS Global Research, Inc.

CRO General Operation (America)

EPS Global Research Pte. Ltd.
(former) Gleneagles CRC Pte Ltd

CRO/SMO General Operation (Asia)

EPS EKISHIN Co., Ltd.
EKISHIN Business
EPS China Co., Ltd.

BPO Operation

Other

EKISHIN Operation Management(Japan)
EKISHIN Operation Management(China)

EPI Japan Co., Ltd.

BPO Operation Service (Japan)

EPS Suzhou Co., Ltd.

BPO Operation Service (China)

EMS Co., Ltd.

BPO Operation Service (Japan)

EPS Yamanashi Co., Ltd.

BPO Operation Service (Japan)

EPBiz Co., Ltd.

Shared Service

LSG Co., Ltd.

Non-Clinical Trial Related Operation

3. Group Management Structure
In order to clarify the management and corporate functions of each business segment across the Group, wewill promote our group operations with responsibilities and authorities of the following management teams:(1) Operating Department
Domestic CRO

Tanaka, Managing Officer, EPS Corporation

Domestic SMO

Ando, President, EP-Mint Co., Ltd.

Domestic CSO

Nishizuka, President, EP-PharmaLine Co., Ltd.

GR Business

Weng, President, EPS International Holdings Co., Ltd.

EKISHIN Business

Yan, President, EPS EKISHIN Co., Ltd.

BPO Operation

Abe, Corporate Officer, EPS Corporation(2) Corporate Function
Corporate Strategy Division

Sekitani, Managing Officer, EPS Corporation

Corporate Administration Division

Orihashi, Managing Officer, EPS Corporation

4. Future Business Outlook(1) Business Theme
We will expand our future business based on the following five themes:① Aim to be No.1 in CRO+SMO domestically② Aim to be a leading company in CSO domestically③ Aim to be a leading company for Global Research in Asia Pacific④ Promote EKISHIN Operation as new engines of growth⑤ Promote efficiency through BPO(2) Quantitative Targets (Fiscal Year September 2018)
We aim for consolidated net sales of 60-75 billion yen and operating income of 7-10 billion yen by fiscal year
September 2018. For the breakdown, based on an average growth rate of 10% for 35 billion yen sales infiscal year September 2014, we aim for 52 billion yen by fiscal year September 2018 for our three domestic
operations. For our two overseas operations, based on an average growth rate of 25% for 6 billion yen infiscal year September 2014, we aim for 15 billion yen by fiscal year September 2018.

Please see below for more details.
(Units: 100 million yen, %)Fiscal Year September 2014

Domestic CRO

232.3

34.7

14.9%

Fiscal Year September 2018
Operating
Average Sales
Margin orNet Sales
Growth Rate
value
300.0~350.0
6.6%~10.8% 15.0~16.5%

Domestic SMO

65.0

9.0

13.8%

80.0~100.0

5.3%~11.4%

13.5~15.0%

Domestic CSO

57.0

1.1

1.9%

80.0~100.0

8.8%~15.1%

7.0~10.0%

GR Business25.0-0.4-

45.0~60.0

15.8%~24.5%

5.0~10.0%

EKISHIN Business36.0-0.5-

80.0~120.0

22.1%~35.1%

5.0~10.0%

BPO Operation*

6.2

0.6

10.0%

15.0~20.0

24.8%~34.1%

5.0%

409.6

41.1

10.0%

600.0~750.0

10.0%~16.3%

70~100Net Sales

Consolidated

OperatingOperatingincomeMargin* BPO Operation does not include sales from inter-segments.